 |
|
Serum Immunoreactive Erythropoietin in HIV-Infected Patients
Jerry L. Spivak, MD;
David C. Barnes, MD;
Edward Fuchs, PA;
Thomas C. Quinn, MD
JAMA. 1989;261(21):3104-3107.
Abstract
| |
Serum immunoreactive erythropoietin (SIE) and hemoglobin levels were measured in 152 patients infected with the human immunodeficiency virus. Anemia was present in 18% of asymptomatic patients who tested positive for the human immunodeficiency virus, 50% of patients with a condition related to the acquired immunodeficiency syndrome (AIDS), and 75% of patients with AIDS. The mean SIE level for untreated AIDS patients (26.2±2.4 mU/mL) was greater than for patients who tested positive for human immunodeficiency virus or patients with an AIDS-related condition but not outside the normal range for SIE (4 to 26 mU/mL), and the incremental increase in SIE level for a given decline in hemoglobin level was much less in AIDS patients than in patients with uncomplicated iron deficiency anemia. Forty-two patients were treated with zidovudine, and the hemoglobin level fell 10 g/L or more in 48%. In contrast to the untreated patients, however, the mean SIE level rose 10-fold to 214 mU/mL, and the incremental change in SIE level for a given decline in hemoglobin level was markedly increased. In the zidovudine-treated patients, erythrocyte mean corpuscular volume also rose significantly from a mean of 88.1 fL to 102 fL. However, in only 1 patient was there a corresponding increase in reticulocytes and in none was there amelioration of anemia. The data indicate that SIE level is inappropriately low in anemic AIDS patients. The ability of these patients to produce erythropoietin is intact and can be expressed with zidovudine therapy. However, even very high levels of SIE fail to stimulate erythropoiesis adequately.
(JAMA. 1989;261:3104-3107)
Author Affiliations
From the Divisions of Hematology (Dr Spivak) and Infectious Disease (Drs Barnes and Quinn and Mr Fuchs), Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Md.
Footnotes
Reprint requests to the Division of Hematology, Blalock 1033, The Johns Hopkins Hospital, 600 N Wolfe St, Baltimore, MD 21205 (Dr Spivak).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Platelet Decline: An Avenue for Investigation Into the Pathogenesis of Human Immunodeficiency Virus Associated Dementia
Wachtman et al.
Arch Neurol 2007;64:1264-1272.
ABSTRACT
| FULL TEXT
Epoetin Alfa: Clinical Evolution of a Pleiotropic Cytokine
Henry et al.
Arch Intern Med 2004;164:262-276.
ABSTRACT
| FULL TEXT
Human Immunodeficiency Virus Hematology
Volberding et al.
ASH Education Book 2003;2003:294-313.
ABSTRACT
| FULL TEXT
Iron Deficiency Anemia Is Highly Prevalent among Human Immunodeficiency Virus-Infected and Uninfected Infants in Uganda
Totin et al.
J. Nutr. 2002;132:423-429.
ABSTRACT
| FULL TEXT
Erythropoietin, iron, and erythropoiesis
Goodnough et al.
Blood 2000;96:823-833.
ABSTRACT
| FULL TEXT
Epidemiology of Anemia in Human Immunodeficiency Virus (HIV)-Infected Persons: Results From the Multistate Adult and Adolescent Spectrum of HIV Disease Surveillance Project
Sullivan et al.
Blood 1998;91:301-308.
ABSTRACT
| FULL TEXT
Recombinant Human Erythropoietin (rHuEPO) for the Treatment of the Anemia of Cancer
Abels et al.
The Oncologist 1996;1:140-150.
ABSTRACT
| FULL TEXT
Erythropoietin: Biology and Clinical Applications
Tabbara
Arch Intern Med 1993;153:298-304.
ABSTRACT
Recombinant Human Erythropoietin in the Treatment of Anemia Associated with Human Immunodeficiency Virus (HIV) Infection and Zidovudine Therapy: Overview of Four Clinical Trials
Henry et al.
ANN INTERN MED 1992;117:739-748.
ABSTRACT
Persistent B19 Parvovirus Infection in Patients Infected with Human Immunodeficiency Virus Type 1 (HIV-1): A Treatable Cause of Anemia in AIDS
Frickhofen et al.
ANN INTERN MED 1990;113:926-933.
ABSTRACT
|
